Results 211 to 220 of about 31,169 (289)

Hydro‐ and Lipophilicity of Molecular‐Size‐Controlled Hydrogel Drug Carriers

open access: yesAdvanced Materials Technologies, EarlyView.
We investigate nano‐sized hydrogel drug carriers with tailored hydro‐ and lipophilicity. We design their encapsulation and structure‐forming capabilities and follow them in real time during fabrication using time‐resolved and in situ grazing incidence x‐ray scattering.
Elisabeth Erbes   +21 more
wiley   +1 more source

Magnetic Micro‐ and Nanorobots for Precision Thrombolysis: Design Strategies and Translational Challenges

open access: yesAdvanced Robotics Research, EarlyView.
Micro‐ and nanorobots for targeted thrombolysis. This perspective elaborates on the clinical indication of blood clot disorders and current limitations for treatment. As a novel, alternative solution, micro‐ and nanorobots can be used to treat and break down thrombi.
Joshua M. Mesfin   +3 more
wiley   +1 more source

The Kallikrein-Kinin System: Proteolytic Orchestrators of Tissue Barrier Disruption in Inflammation and Cancer. [PDF]

open access: yesInt J Mol Sci
Cárdenas-Oyarzo A   +5 more
europepmc   +1 more source

Chemical Screening Identifies Danofloxacin as a Self‐Renewal Agonist of Embryonic Stem Cells through Alleviation of HDAC1‐Mediated Deacetylation of Tert and Prdm10

open access: yesAdvanced Science, EarlyView.
This study identified Danofloxacin as a novel supporter of the maintenance of mouse embryonic stem cell (ESC) pluripotency. It functions partially by inhibiting HDAC1, which increases specific histone acetylation marks and activates key genes like Tert and Prdm10.
Yan Zhang   +8 more
wiley   +1 more source

Whole Genome Sequence of <i>Xylaria chamelensis</i> (Xylariales, Ascomycota), A New Species Associated with Fabaceae Pods. [PDF]

open access: yesMycobiology
Osorio-Navarro Y   +6 more
europepmc   +1 more source

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

open access: yesAdvanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy